Kalaris Therapeutics, Inc.
KLRS
$5.54
$0.071.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 97.65% | 290.98% | 618.27% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | -66.34% | 192.72% | 303.98% | ||
| Operating Income | 66.34% | -192.72% | -303.98% | ||
| Income Before Tax | 68.77% | -100.88% | -199.27% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 68.77% | -100.88% | -199.27% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 68.77% | -100.88% | -199.27% | ||
| EBIT | 66.34% | -192.72% | -303.98% | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | 97.74% | 85.76% | 3.09% | ||
| Normalized Basic EPS | 97.74% | 85.76% | 3.09% | ||
| EPS Diluted | 97.74% | 85.76% | 3.09% | ||
| Normalized Diluted EPS | 97.74% | 85.76% | 3.09% | ||
| Average Basic Shares Outstanding | 1,282.95% | 1,310.67% | 208.78% | ||
| Average Diluted Shares Outstanding | 1,282.95% | 1,310.67% | 208.78% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||